<DOC>
	<DOCNO>NCT02346032</DOCNO>
	<brief_summary>Phase II Study Refametinib , MEK inhibitor , second-line treatment advance biliary tract adenocarcinoma</brief_summary>
	<brief_title>Phase II Study Refametinib , MEK Inhibitor , Second-line Treatment Advanced Biliary Tract Adenocarcinoma</brief_title>
	<detailed_description>Refametinib administer orally start dose 50 mg twice daily continuous daily dose schedule . Self-administration refametinib tablet take place outpatient basis . Patients experience dose-limiting toxicity attribute study medication least 1-week treatment break insert continuous daily dose period need and/or may interrupt reduce depend individual tolerability .</detailed_description>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Biliary Tract Neoplasms</mesh_term>
	<criteria>1. age ≥ 18 2. histologically cytologically confirm adenocarcinoma biliary tract 3. unresectable metastatic 4 . ECOG performance status 0~2 5. measurable lesion per RECIST 1.1 criterion 6. adequate marrow , hepatic , renal function 7. normal range cardiac function confirm echocardiogram within 1 year ( LVEF ≥50 ) 8 . ChildPugh Class A case liver cirrhosis 9 . One prior treatment cytotoxic chemotherapy ( include adjuvant treatment within 12 month ) 10 . Resolution acute toxic effect prior therapy Common Toxicity Criteria Adverse Events ( CTCAE 4.03 ) ≤ grade 1 . 11. provision sign write informed consent 1 . History cardiac disease 2 . Ongoing infection &gt; Grade 2 accord NCICTCAE version 4.03 . Hepatitis B allow active replication ( define abnormal ALT &gt; 2xULN associate HBV DNA &gt; 20,000 IU/mL ) present 3 . Severe comorbid illness and/or active infection include active hepatitis C human immunodeficiency virus ( HIV ) infection 4 . History interstitial lung disease ( ILD ) . 5 . Any cancer curatively treat &lt; 3 year prior study entry , except cervical carcinoma situ , treat basal cell carcinoma , superficial bladder tumor ( Staging : Ta , Tis T1 ) . 6 . Renal failure require hemo peritoneal dialysis . 7 . Clinically significant GI bleeding ( CTCAE 4.03 grade 3 high ) within 30 day prior start screen 8 . Thrombotic embolic event cerebrovascular accident ( include transient ischemic attack ) within 6 month prior start screen . 9 . History organ allograft , cornea transplantation allow 10 . Active CNS metastasis controllable radiotherapy corticosteroid 11 . Visible retinal pathology assess ophthalmologic exam consider risk factor RVO CSR . 12 . Known history hypersensitivity study drug 13 . Any condition unstable could jeopardize safety patient his/her compliance study 14 . Nonhealing wound , ulcer , bone fracture . 15 . Patients seizure disorder require medication . 16 . Use strong inhibitor CYP3A4 strong inducer CYP3A4 stop 2 week start screen ( see Appendix 1 ) . 17 . Acute steroid therapy taper purpose ( chronic steroid therapy acceptable provide dose stable 1 month start screen thereafter ) . 18 . Substance abuse , medical , psychological social condition may interfere patient 's participation study evaluation study result . 19 . Pregnant lactating woman . Women childbearing potential employ adequate contraception . Women childbearing potential must negative serum pregnancy test perform within 7 day prior start study treatment negative result must document first dose study drug .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>second line</keyword>
</DOC>